Literature DB >> 25045002

Hepatic artery and biliary complications in liver transplant recipients undergoing pretransplant transarterial chemoembolization.

Aparna Goel1, Neil Mehta, Jennifer Guy, Nicholas Fidelman, Francis Yao, John Roberts, Norah Terrault.   

Abstract

Liver transplantation (LT) is the treatment of choice for patients with cirrhosis and hepatocellular carcinoma (HCC) not amenable to resection. Locoregional therapies for HCC are often used to reduce tumor burden, bridge patients to LT, and down-stage HCC so that patients are eligible for LT. We hypothesized that prior endovascular antitumor therapy may increase the risk of hepatic artery (HA) and biliary complications after LT. The aim of this study was to compare HA and biliary complications in LT recipients with HCC who received transarterial chemoembolization (TACE) before LT with complications in LT recipients with HCC who did not receive TACE before LT. This was a retrospective cohort study of HCC patients at two transplant centers. The prevalence of HA complications (HA thrombosis, stenosis, or pseudoaneurysm) and biliary complications (nonanastomotic stricture, bile leak, and diffuse injury) were compared between patients treated with or without TACE. There were 456 HCC patients with a median age of 61 years (77% were male, and 63% had hepatitis C virus), and 328 (72%) received TACE before LT. The overall prevalence of HA complications was 4.7% in the no-TACE group and 7.9% in the TACE group (P = 0.22). All HA stenosis complications (n = 14) occurred in the TACE group (P = 0.018 versus the no-TACE group). An older donor age and a lower albumin level significantly increased the odds of HA complications. There was a nonstatistically significant increased odds of HA complications in the TACE group versus the no-TACE group according to an adjusted analysis (odds ratio = 2.02, 95% confidence interval = 0.79-5.16, P = 0.14). The overall prevalence of biliary complications was 16.4% in the no-TACE group and 19.8% in the TACE group (P = 0.40). In conclusion, a lower pre-LT albumin level and an older donor age were significantly associated with higher odds of HA complications after LT. TACE was not associated with higher odds of overall HA complications but was associated with a higher prevalence of HA stenosis. Further studies are warranted to confirm the HA stenosis findings and elucidate the pathogenesis.
© 2014 American Association for the Study of Liver Diseases.

Entities:  

Mesh:

Year:  2014        PMID: 25045002      PMCID: PMC4804463          DOI: 10.1002/lt.23945

Source DB:  PubMed          Journal:  Liver Transpl        ISSN: 1527-6465            Impact factor:   5.799


  27 in total

1.  Impact of geographic disparity on liver allocation for hepatocellular cancer in the United States.

Authors:  Zakiyah Kadry; Eric W Schaefer; Tadahiro Uemura; Ali Riaz Shah; Ian Schreibman; Thomas R Riley
Journal:  J Hepatol       Date:  2011-10-23       Impact factor: 25.083

2.  Screening for hepatocellular carcinoma: the rationale for the American Association for the Study of Liver Diseases recommendations.

Authors:  Morris Sherman; Jordi Bruix; Michael Porayko; Tram Tran
Journal:  Hepatology       Date:  2012-07-30       Impact factor: 17.425

3.  Impact of center volume on outcomes of increased-risk liver transplants.

Authors:  Deepak K Ozhathil; You Fu Li; Jillian K Smith; Jennifer F Tseng; Reza F Saidi; Adel Bozorgzadeh; Shimul A Shah
Journal:  Liver Transpl       Date:  2011-10       Impact factor: 5.799

4.  Hepatic arterial complications in liver transplant recipients treated with pretransplantation chemoembolization for hepatocellular carcinoma.

Authors:  H M Richard; J E Silberzweig; H A Mitty; W Y Lou; J Ahn; J M Cooper
Journal:  Radiology       Date:  2000-03       Impact factor: 11.105

5.  Prognosis of hepatocellular carcinoma: the BCLC staging classification.

Authors:  J M Llovet; C Brú; J Bruix
Journal:  Semin Liver Dis       Date:  1999       Impact factor: 6.115

6.  Bridging locoregional therapy for hepatocellular carcinoma prior to liver transplantation.

Authors:  Jason T Heckman; Michael B Devera; J Wallis Marsh; Paulo Fontes; Nikhil B Amesur; Shane E Holloway; Michael Nalesnik; David A Geller; Jennifer L Steel; T Clark Gamblin
Journal:  Ann Surg Oncol       Date:  2008-08-12       Impact factor: 5.344

7.  Liver transplantation for hepatocellular carcinoma: analysis of survival according to the intention-to-treat principle and dropout from the waiting list.

Authors:  Francis Y Yao; Nathan M Bass; Bev Nikolai; Timothy J Davern; Robert Kerlan; Victor Wu; Nancy L Ascher; John P Roberts
Journal:  Liver Transpl       Date:  2002-10       Impact factor: 5.799

8.  Excellent outcome following down-staging of hepatocellular carcinoma prior to liver transplantation: an intention-to-treat analysis.

Authors:  Francis Y Yao; Robert K Kerlan; Ryutaro Hirose; Timothy J Davern; Nathan M Bass; Sandy Feng; Marion Peters; Norah Terrault; Chris E Freise; Nancy L Ascher; John P Roberts
Journal:  Hepatology       Date:  2008-09       Impact factor: 17.425

9.  Hepatocellular carcinoma incidence, mortality, and survival trends in the United States from 1975 to 2005.

Authors:  Sean F Altekruse; Katherine A McGlynn; Marsha E Reichman
Journal:  J Clin Oncol       Date:  2009-02-17       Impact factor: 44.544

10.  Management of hepatocellular carcinoma: an update.

Authors:  Jordi Bruix; Morris Sherman
Journal:  Hepatology       Date:  2011-03       Impact factor: 17.425

View more
  8 in total

Review 1.  Strategies to improve outcome of patients with hepatocellular carcinoma receiving a liver transplantation.

Authors:  Marta Guerrero-Misas; Manuel Rodríguez-Perálvarez; Manuel De la Mata
Journal:  World J Hepatol       Date:  2015-04-08

2.  Preresection transarterial chemoembolization for hepatocellular carcinoma.

Authors:  Sim Sai Tin; Viroj Wiwanitkit
Journal:  Indian J Gastroenterol       Date:  2015-03

3.  Early Hepatic Artery Thrombosis After Liver Transplantation: What is the Impact of the Arterial Reconstruction Type?

Authors:  Astrid Herrero; Regis Souche; Emmanuel Joly; Gildas Boisset; Hussein Habibeh; Hassan Bouyabrine; Fabrizio Panaro; Jose Ursic-Bedoya; Samir Jaber; Boris Guiu; Georges Philippe Pageaux; Francis Navarro
Journal:  World J Surg       Date:  2017-08       Impact factor: 3.352

4.  Bridging treatment prior to liver transplantation for hepatocellular carcinoma: radioembolization or transarterial chemoembolization?

Authors:  Tamás Benkö; Julia König; Jens M Theysohn; Clemens Schotten; Fuat H Saner; Jürgen Treckmann; Sonia Radunz
Journal:  Eur J Med Res       Date:  2022-05-26       Impact factor: 4.981

5.  Gadolinium ethoxybenzyl diethylenetriamine pentaacetic acid-enhanced magnetic resonance imaging: A potential utility for the evaluation of regional liver function impairment following transcatheter arterial chemoembolization.

Authors:  Yu-Dong Xiao; Ramchandra Paudel; Huan Liu; Bin Zhang; Cong Ma; Shun-Ke Zhou
Journal:  Oncol Lett       Date:  2014-12-23       Impact factor: 2.967

6.  Common ultrasound and contrast-enhanced ultrasonography in the diagnosis of hepatic artery pseudoaneurysm after liver transplantation.

Authors:  Xiuyun Ren; Yukun Luo; Nong Gao; Hong Niu; Jie Tang
Journal:  Exp Ther Med       Date:  2016-05-17       Impact factor: 2.447

7.  The role of the comprehensive complication index for the prediction of survival after liver transplantation.

Authors:  Quirino Lai; Fabio Melandro; Greg Nowak; Daniele Nicolini; Samuele Iesari; Elisa Fasolo; Gianluca Mennini; Antonio Romano; Federico Mocchegiani; Kevin Ackenine; Marina Polacco; Laura Marinelli; Olga Ciccarelli; Giacomo Zanus; Marco Vivarelli; Umberto Cillo; Massimo Rossi; Bo-Göran Ericzon; Jan Lerut
Journal:  Updates Surg       Date:  2020-09-06

8.  Prospective Study of Stereotactic Body Radiation Therapy for Hepatocellular Carcinoma on Waitlist for Liver Transplant.

Authors:  Tiffany Cho-Lam Wong; Victor Ho-Fun Lee; Ada Lai-Yau Law; Herbert H Pang; Ka-On Lam; Vince Lau; Tracy Yushi Cui; Adrianna Sze-Yin Fong; Sarah Wai-Man Lee; Edwin Chun-Yin Wong; Jeff Wing-Chiu Dai; Albert Chi-Yan Chan; Tan-To Cheung; James Yan-Yue Fung; Rebecca Mei-Wan Yeung; Mai-Yee Luk; To-Wai Leung; Chung-Mau Lo
Journal:  Hepatology       Date:  2021-09-30       Impact factor: 17.298

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.